| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-708
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2014-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed00b1137e7ec42504730d0246d875a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2d18063ae3606d8393b025adc865c6b |
| publicationDate |
2022-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2907924-C |
| titleOfInvention |
Telomerase mediated telomere altering compounds |
| abstract |
The present disclosure is directed toward a pharmaceutical compound for the treatement of lung cancer or colon cancer, wherein the pharmaceutical compound is a compound having the following formula: where Rl is H, or a pharmaceutically acceptable salt thereof The pharmaceutical compound can be convereted into telomere substrates in vivo and can be recognized by telomerase for incorporation into telomeres of telomerase active cells, leading to induction of cell death of the telomerase active cells. |
| priorityDate |
2013-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |